Medical Device and In Vitro Diagnostics Deal Statistics Quarterly, Q4 2007
Highlights from the Q4 2007 review of medical device and in vitro diagnostics/research dealmaking: there was a boost in medical device acquisitions--with patient monitoring in particular, which accounted for about half the total of this period--capping off an impressive year in medtech M&A activity. Of note in the in vitro diagnostics/research space was glucose monitoring, which brought in 60% of the total GM segment's $160 million in financing for the entire year.
You may also be interested in...
Situations look bleak for medical device IPOs interested in going public, but venture investors in companies that went public last year are beginning to sell or divest some of their shares.
Intuitive Surgical is the closest thing the health care industry has to Google Inc. With shares trading at or around $300 at publishing time, the robotic surgery pioneer clearly leads the field in a review of five-year and one-year stock valuations of publicly-traded medical device companies conducted by IN VIVO. According to this survey, over the past five years, public investors have shown a strong level of support for the stock of companies with a laser-like focus on a single market area.
Small company DexCom, finds itself a leader in continuous glucose monitoring, the hottest new segment of glucose monitoring, a business otherwise dominated by giant companies. Continuous glucose monitoring (CGM) is all the buzz at diabetes and critical care clinical meetings these days. CGM systems give diabetic patients in the home (or the hospital) glucose readings at any hour of the day without the need to get out the finger-stick testing paraphernalia. More than that, though, CGM is a new tool for achieving tight glycemic control, and avoiding the excursions above and below the normal glucose levels, which are responsible for the hospitalizations as well as the long-term harmful consequences of diabetes. As a frontrunner in the field, DexCom shares with Medtronic the challenge of proving the value of CGM to payers, especially since the task involves throwing over the gold standard by which successful glycemic control is measured-the HbA1c test.